SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

NCT05057806 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Type2 Diabetes
Heart Failure With Preserved Ejection Fraction

Interventions

DRUG: Empagliflozin 25 MG
DRUG: Placebo

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

[object Object]
[object Object]